Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company's segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Pharmaceuticals - NEC
- Sub-Industry: N/A
- Symbol: NYSE:SNY
- CUSIP: N/A
- Web: www.sanofi.com
- Market Cap: $120.27347 billion
- Outstanding Shares: 2,525,475,000
- 50 Day Moving Avg: $48.25
- 200 Day Moving Avg: $45.52
- 52 Week Range: $36.81 - $50.24
Sales & Book Value:
- Trailing P/E Ratio: 11.59
- Foreward P/E Ratio: 14.31
- P/E Growth: 1.53
- Annual Revenue: $40.94 billion
- Price / Sales: 2.97
- Book Value: $25.96 per share
- Price / Book: 1.85
- Annual Dividend: $1.10
- Dividend Yield: 2.3%
- EBIDTA: $12.09 billion
- Net Margins: 26.55%
- Return on Equity: 25.89%
- Return on Assets: 14.24%
- Debt-to-Equity Ratio: 0.29%
- Current Ratio: 1.62%
- Quick Ratio: 1.20%
- Average Volume: 1.89 million shs.
- Beta: 0.89
- Short Ratio: 1.35
Frequently Asked Questions for Sanofi (NYSE:SNY)
What is Sanofi's stock symbol?
Sanofi trades on the New York Stock Exchange (NYSE) under the ticker symbol "SNY."
How often does Sanofi pay dividends? What is the dividend yield for Sanofi?
Sanofi announced an annual dividend on Friday, February 17th. Investors of record on Monday, May 15th will be paid a dividend of $1.5771 per share on Wednesday, June 7th. This represents a yield of 3.65%. The ex-dividend date of this dividend is Thursday, May 11th. This is a positive change from Sanofi's previous annual dividend of $1.10. View Sanofi's Dividend History.
How were Sanofi's earnings last quarter?
Sanofi (NYSE:SNY) posted its quarterly earnings data on Friday, April, 28th. The company reported $0.76 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.73 by $0.03. The business earned $8.65 billion during the quarter, compared to analysts' expectations of $8.40 billion. Sanofi had a net margin of 26.55% and a return on equity of 25.89%. The firm's quarterly revenue was up 1.2% on a year-over-year basis. View Sanofi's Earnings History.
Where is Sanofi's stock going? Where will Sanofi's stock price be in 2017?
13 brokers have issued 1 year price targets for Sanofi's stock. Their predictions range from $55.00 to $93.00. On average, they expect Sanofi's share price to reach $74.00 in the next twelve months. View Analyst Ratings for Sanofi.
Who are some of Sanofi's key competitors?
Some companies that are related to Sanofi include Novartis AG (NVS), Pfizer (PFE), Merck & Company (MRK), Novo Nordisk A/S (NVO), GlaxoSmithKline PLC (GSK), Eli Lilly and Company (LLY), Bristol-Myers Squibb Company (BMY), Abbott Laboratories (ABT), Astrazeneca PLC (AZN), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHPG), Shire PLC (SHP), Teva Pharmaceutical Industries Limited (TEVA), Dr. Reddy's Laboratories Ltd (RDY), Valeant Pharmaceuticals International (VRX), Patheon NV (PTHN) and Taro Pharmaceutical Industries (TARO).
Who are Sanofi's key executives?
Sanofi's management team includes the folowing people:
- Serge Weinberg, Independent Chairman of the Board
- Olivier Brandicourt, Chairman of the Executive Committee, Chief Executive Officer, Director
- Jerome Contamine, Executive Vice President, Chief Financial Officer, Member of the Executive Committee and the Senior Leadership Team
- Karen Marie Linehan, Executive Vice President, Legal Affairs and General Counsel, Member of the Executive Committee and the Senior Leadership Team
- Olivier Charmeil, Executive Vice President and General Manager, General Medicines & Emerging Markets, Member of the Executive Committee and the Senior Leadership Team
- Peter Guenter, Executive Vice President and General Manager, Diabetes & Cardiovascular, Member of the Executive Committee and the Senior Leadership Team
- Carsten Hellmann, Executive Vice President and General Manager of Merial, Member of the Executive Committee and the Senior Leadership Team
- David Loew, Executive Vice President and General Manager of Sanofi Pasteur, Member of the Executive Committee and the Senior Leadership Team
- David P. Meeker M.D., Executive Vice President and General Manager of Sanofi Genzyme, Member of the Executive Committee and the Senior Leadership Team
- Roberto Pucci, Executive Vice President, Human Resources, Member of the Executive Committee and the Senior Leadership Team
Who owns Sanofi stock?
Sanofi's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Fisher Asset Management LLC (0.54%), Aperio Group LLC (0.03%), Russell Investments Group Ltd. (0.02%), Foundation Resource Management Inc. (0.01%), Bank of Montreal Can (0.01%) and Manning & Napier Advisors LLC (0.01%). View Institutional Ownership Trends for Sanofi.
Who sold Sanofi stock? Who is selling Sanofi stock?
Sanofi's stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Douglas Lane & Associates LLC, Jarislowsky Fraser Ltd, Country Club Trust Company n.a., Cribstone Capital Management LLC, Capstone Asset Management Co., Fulton Bank N.A. and CENTRAL TRUST Co. View Insider Buying and Selling for Sanofi.
Who bought Sanofi stock? Who is buying Sanofi stock?
Sanofi's stock was purchased by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Aperio Group LLC, Russell Investments Group Ltd., Capital Asset Advisory Services LLC, Boston Advisors LLC, Gradient Investments LLC, Cullinan Associates Inc. and Visionary Asset Management Inc.. View Insider Buying and Selling for Sanofi.
How do I buy Sanofi stock?
Shares of Sanofi can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sanofi's stock price today?
MarketBeat Community Rating for Sanofi (NYSE SNY)MarketBeat's community ratings are surveys of what our community members think about Sanofi and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Sanofi stock can currently be purchased for approximately $48.07.
Consensus Ratings for Sanofi (NYSE:SNY) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||2 Sell Ratings, 7 Hold Ratings, 4 Buy Ratings|
|Consensus Rating:||Hold (Score: 2.15)|
|Consensus Price Target: ||$74.00 (53.94% upside)|
Analysts' Ratings History for Sanofi (NYSE:SNY)
(Data available from 7/26/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|6/9/2017||Argus||Boost Price Target||Buy||$50.00 -> $55.00||Low|
|5/11/2017||Berenberg Bank||Downgrade||Buy -> Hold||Low|
|4/20/2017||J P Morgan Chase & Co||Reiterated Rating||Neutral||Medium|
|4/7/2017||HSBC Holdings plc||Downgrade||Hold -> Reduce||Low|
|3/9/2017||Liberum Capital||Initiated Coverage||Hold -> Hold||Low|
|3/7/2017||Barclays PLC||Initiated Coverage||Underweight||N/A|
|2/9/2017||Natixis||Upgrade||Neutral -> Buy||N/A|
|1/10/2017||Leerink Swann||Reiterated Rating||Outperform||N/A|
|1/8/2017||Goldman Sachs Group, Inc. (The)||Reiterated Rating||Hold||N/A|
|11/29/2016||Morgan Stanley||Upgrade||Equal Weight -> Overweight||N/A|
|9/23/2016||Piper Jaffray Companies||Initiated Coverage||Neutral||N/A|
|9/14/2016||Jefferies Group LLC||Reiterated Rating||Hold||N/A|
|9/13/2016||BNP Paribas||Upgrade||Underperform -> Neutral||N/A|
|6/28/2016||Citigroup Inc.||Reiterated Rating||Neutral||N/A|
|5/3/2016||Bank of America Corporation||Reiterated Rating||Buy||$58.00||N/A|
|4/12/2016||Chardan Capital||Reiterated Rating||Buy||N/A|
|2/10/2016||Sanford C. Bernstein||Lower Price Target||Market-Perform||$52.00 -> $45.00||N/A|
|11/9/2015||Bryan, Garnier & Co||Reiterated Rating||Buy -> Neutral||N/A|
|9/16/2015||Sarasin & Partners||Upgrade||Buy||N/A|
Earnings History for Sanofi (NYSE:SNY)Earnings History by Quarter for Sanofi (NYSE SNY)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|4/28/2017||3/31/2017||$0.73||$0.76||$8.40 billion||$8.65 billion||View||N/A|
|2/8/2017||Q416||$0.66||$0.67||$9.87 billion||$8.88 billion||View||N/A|
|10/29/2015||Q315||$0.88||$0.89||$10.97 billion||$10.67 billion||View||N/A|
|4/30/2015||Q115||$0.61||$0.73||$9.21 billion||$9.78 billion||View||N/A|
|2/5/2015||Q4||$0.89||$0.79||$11.34 billion||$10.39 billion||View||N/A|
|7/31/2014||Q2||$0.79||$0.72||$11.19 billion||$10.82 billion||View||N/A|
|4/29/2014||Q114||$0.84||$0.81||$11.19 billion||$10.88 billion||View||N/A|
Earnings Estimates for Sanofi (NYSE:SNY)
2017 EPS Consensus Estimate: $3.21
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Current Dividend Information for Sanofi (NYSE:SNY)
|Most Recent Dividend:||6/7/2017|
|Dividend Growth:||-2.50% (3 Year Average)|
|Payout Ratio:||27.64% (Trailing 12 Months of Earnings) |
34.38% (Based on This Year's Estimates)
32.74% (Based on Next Year's Estimates)
Dividend History by Quarter for Sanofi (NYSE SNY)
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading and Institutional Ownership History for Sanofi (NYSE:SNY)
Insider Ownership Percentage: 1.00%Insider Trades by Quarter for Sanofi (NYSE:SNY)
Institutional Ownership Percentage: 9.97%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|7/9/2014||Sanofi||Major Shareholder||Buy||195,000||$308.27||$60,112,650.00|| |
|7/8/2014||Sanofi||Major Shareholder||Buy||153,000||$311.67||$47,685,510.00|| |
Headline Trends for Sanofi (NYSE:SNY)
Latest Headlines for Sanofi (NYSE:SNY)
Sanofi (SNY) Chart for Wednesday, July, 26, 2017